Shire share price opens lower as group says medical trial unsuccessful

on Apr 9, 2015
Updated: Oct 21, 2019

Shire Plc’s (LON:SHP) shares opened London’s session lower today after the rare disease specialist said earlier this morning that its Phase 2 trial of an investigational compound to treat a life-threatening genetic disorder in children had failed to meet the primary or secondary endpoints.

Shire’s shares were down 0.55 percent at 5,455.00p as of 08:03 BST while the FTSE 100 index was up 0.46 percent and the Healthcare index was advancing 0.82 percent.
The pharmaceutical company tested for 13 weeks the SHP625 (LUM001) compound in a study of 20 paediatric patients with Alagille syndrome (ALGS), a rare life-treatening generic disorder which occurrs in around one in 30,000 live births and affects the liver, heart, kidneys and other systems of the body.
The Phase 2 randomised, placebo-controlled study was carried out on children with ALGS aged one to 18 years in the United Kingdom.
Philip J. Vickers, Ph.D., Head of Research and Development, Shire, said:
“We have gained important insights from these first results from one of several phase 2 studies in the SHP625 development program.”
The company pledges to pursue the ongoing studies of SHP625 in ALGS and other indications, Vickers noted.
Shire is currently carrying out two larger placebo-controlled phase 2 studies in ALGS. The group is also studying the SHP625 compound to assess whether it could use it to treat progressive familial intrahepatic cholestasis, primary biliary cirrhosis and primary sclerosing cholangitis.
As of 08:26 BST, Thursday, 09 April, Shire PLC share price is 5,485.00p.

Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.


Want easy-to-follow crypto, forex & stock trading signals? Make trading simple by copying our team of pro-traders. Consistent results. Sign-up today at Invezz Signals.

Learn more
Health & pharma Stock Market